Golestan University of Medical Sciences Repository

Modeling of different treatment strategies for hemophilia with inhibitors

Mirbehbahani, N. (2008) Modeling of different treatment strategies for hemophilia with inhibitors. HAEMOPHILIA, 14 (s2). p. 51.

Full text not available from this repository.


The development of inhibitor alloantibody to factor VIII is a major complication in the management of hemophilia, occurring in 10–30% of hemophilia A. When present the inhibitor inactivates the biological activity of infused F VIII, making the patient refractory to treatment. For patients with low titer inhibitors ( < 5 BU) to F VIII highdose F VIII was a therapeutic option to overcome the inhibitors. This paper reports a systemic review of the cost-effectiveness of treatment options in patients with hemophilia A with low titer inhibitors. Method: The study used a longitudinal before and after design and was conducted in two phases. Phase I was 6 months preceding the introduction of rFVIIa, during which patients received on-demand usual care with recombinant factor VIII regimes. Phase 2 was 6 months treatment on rFVIIa assessed retrospectively. Finding: We determined the clinical response, effect on quality of life and the costeffectiveness of treatment with NovoSeven in 3 boys with low titer inhibitors to factor VIII compared with other treatment regimes previously used in these patients (recombinant factor VIII). Result: Our results indicate that treating hemophilia with recombinant activated factor VII is cost-effective compared to treatment with recombinant factor VIII regimes. Conclusion: Our results confirm that rFVIIa is clinically effective and resulted in 100% reduction in the number of re-treatment emergency room visits compared with the patients with recombinant factor VIII.

Item Type: Article
Subjects: موارد کلی
Divisions: معاونت تحقیقات و فناوری
Depositing User: GOUMS
Date Deposited: 27 Apr 2015 10:43
Last Modified: 21 Jun 2017 18:19
URI: http://eprints.goums.ac.ir/id/eprint/4092

Actions (login required)

View Item View Item